Role of Single-Agent vs Dual IO Evolves in Metastatic Melanoma
November 3rd 2023The role of immunotherapy continues to evolve for the treatment of patients with skin cancer, now with physicians able to choose between the use of single-agent vs dual immunotherapy treatments. In 2 separate Case-Based Roundtable events led by Alan Tan, MD, and Douglas B. Johnson, MD, MSCI, physicians considered these options for a patient with metastatic melanoma.
Lenvatinib/Pembrolizumab Plus Chemotherapy Shows Manageable Toxicity in mESCC
October 23rd 2023The safety run-in of the LEAP-014 trial showed acceptable toxicity and antitumor responses in patients with metastatic esophageal cancer receiving pembrolizumab, lenvatinib, and chemotherapy consisting of cisplatin plus either paclitaxel or 5-fluororacil.
Leukemia Awareness Month: Biomarker Testing Proves Vital at Every Stage of AML Care
September 12th 2023For Leukemia Awareness Month, Salman Fazal, MD, and Tibor Kovacsovics, MD, discussed the importance of biomarker testing and targeting in diagnosis, prognosis, and treatment of acute myeloid leukemia.
Cancer Immunotherapy Month: Mismatch Repair Deficiency Shapes Tumor-Agnostic Use of Immunotherapy
June 28th 2023The pan-tumor indication for immunotherapy in patients with mismatch repair deficient/microsatellite instability-high cancers has offered new treatment options and emphasized the importance of biomarker testing.
Oncologists Encounter Challenges to Accessing PSMA-Targeted Therapy in Prostate Cancer
June 15th 2023Though the radioligand therapy lutetium Lu 177 vipivotide tetraxetan was approved in 2022 for PSMA-avid patients, several practical considerations have limited its use among patients with prostate cancer.
Fianlimab Plus Cemiplimab Shows Efficacy in PD-1–Pretreated Metastatic Melanoma
June 5th 2023In the combination of fianlimab and cemiplimab, we showed a consistent and reproducible high clinical activity in 3 independent cohorts of patients who were naive to anti–PD-1 in the advanced melanoma setting, says Omid Hamid, MD.
BRCA-Mutated mCRPC Has Worse Outcomes Than Non-BRCA HRR Population
June 4th 2023When comparing patients with metastatic castration-resistant prostate cancer who have homologous recombination repair deficiency mutations, those with BRCA mutations have worse outcomes compared to patients without the BRCA mutation in their disease.